These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

435 related items for PubMed ID: 11865071

  • 1. Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity.
    Hansen WJ, Ohh M, Moslehi J, Kondo K, Kaelin WG, Welch WJ.
    Mol Cell Biol; 2002 Mar; 22(6):1947-60. PubMed ID: 11865071
    [Abstract] [Full Text] [Related]

  • 2. The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma.
    Clifford SC, Astuti D, Hooper L, Maxwell PH, Ratcliffe PJ, Maher ER.
    Oncogene; 2001 Aug 16; 20(36):5067-74. PubMed ID: 11526493
    [Abstract] [Full Text] [Related]

  • 3. The Hsp70 and TRiC/CCT chaperone systems cooperate in vivo to assemble the von Hippel-Lindau tumor suppressor complex.
    Melville MW, McClellan AJ, Meyer AS, Darveau A, Frydman J.
    Mol Cell Biol; 2003 May 16; 23(9):3141-51. PubMed ID: 12697815
    [Abstract] [Full Text] [Related]

  • 4. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease.
    Clifford SC, Cockman ME, Smallwood AC, Mole DR, Woodward ER, Maxwell PH, Ratcliffe PJ, Maher ER.
    Hum Mol Genet; 2001 May 01; 10(10):1029-38. PubMed ID: 11331613
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2.
    Lonergan KM, Iliopoulos O, Ohh M, Kamura T, Conaway RC, Conaway JW, Kaelin WG.
    Mol Cell Biol; 1998 Feb 01; 18(2):732-41. PubMed ID: 9447969
    [Abstract] [Full Text] [Related]

  • 7. The von Hippel-Lindau tumor suppressor protein mediates ubiquitination of activated atypical protein kinase C.
    Okuda H, Saitoh K, Hirai S, Iwai K, Takaki Y, Baba M, Minato N, Ohno S, Shuin T.
    J Biol Chem; 2001 Nov 23; 276(47):43611-7. PubMed ID: 11574546
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex.
    Iwai K, Yamanaka K, Kamura T, Minato N, Conaway RC, Conaway JW, Klausner RD, Pause A.
    Proc Natl Acad Sci U S A; 1999 Oct 26; 96(22):12436-41. PubMed ID: 10535940
    [Abstract] [Full Text] [Related]

  • 10. Inactivation of VHL by tumorigenic mutations that disrupt dynamic coupling of the pVHL.hypoxia-inducible transcription factor-1alpha complex.
    Miller F, Kentsis A, Osman R, Pan ZQ.
    J Biol Chem; 2005 Mar 04; 280(9):7985-96. PubMed ID: 15611064
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Ubiquitination of a novel deubiquitinating enzyme requires direct binding to von Hippel-Lindau tumor suppressor protein.
    Li Z, Na X, Wang D, Schoen SR, Messing EM, Wu G.
    J Biol Chem; 2002 Feb 15; 277(7):4656-62. PubMed ID: 11739384
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
    Zatyka M, da Silva NF, Clifford SC, Morris MR, Wiesener MS, Eckardt KU, Houlston RS, Richards FM, Latif F, Maher ER.
    Cancer Res; 2002 Jul 01; 62(13):3803-11. PubMed ID: 12097293
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins.
    Pause A, Lee S, Worrell RA, Chen DY, Burgess WH, Linehan WM, Klausner RD.
    Proc Natl Acad Sci U S A; 1997 Mar 18; 94(6):2156-61. PubMed ID: 9122164
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein.
    Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, Clifford SC, Maher ER, Pugh CW, Ratcliffe PJ, Maxwell PH.
    J Biol Chem; 2000 Aug 18; 275(33):25733-41. PubMed ID: 10823831
    [Abstract] [Full Text] [Related]

  • 19. Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein.
    Ohh M, Takagi Y, Aso T, Stebbins CE, Pavletich NP, Zbar B, Conaway RC, Conaway JW, Kaelin WG.
    J Clin Invest; 1999 Dec 18; 104(11):1583-91. PubMed ID: 10587522
    [Abstract] [Full Text] [Related]

  • 20. Studying interactions of four proteins in the yeast two-hybrid system: structural resemblance of the pVHL/elongin BC/hCUL-2 complex with the ubiquitin ligase complex SKP1/cullin/F-box protein.
    Pause A, Peterson B, Schaffar G, Stearman R, Klausner RD.
    Proc Natl Acad Sci U S A; 1999 Aug 17; 96(17):9533-8. PubMed ID: 10449727
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.